At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Rabbit Antithymocyte globulin +1 moredrug
Likely dose
Rabbit Antithymocyte globulin 1.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rabbit Anti-thymocyte Globulin Versus IL2 Receptor Antagonists in Combination With Tacrolimus, Corticosteroids and Mycophenolate Mofetil in a Predominantly High Risk Kidney Transplant Population.
In Brief
A clinical study evaluating Rabbit Antithymocyte globulin and Daclizumab for End Stage Renal Disease. Completed, enrolled 200 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of induction therapy with Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionJul 2012
Study CompletionJul 2014
TodayJul 2026
First PostedMar 10, 2009
Enrollment StartMar 1, 2009
Primary CompletionJul 1, 2012
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.3 years ago
Interventions
Rabbit Antithymocyte globulindrug
1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
Daclizumabdrug
1.0 mg/kg pre-op and 1.0 mg/kg on Day 7